Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Shares Outstanding (Weighted Average) (2021 - 2025)

Bioventus' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $66.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.21% year-over-year to $66.6 million; the TTM value through Dec 2025 reached $66.6 million, up 3.21%, while the annual FY2025 figure was $66.6 million, 3.21% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $66.6 million in Q4 2025 per BVS's latest filing, roughly flat from $66.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $66.6 million in Q4 2025 to a low of $41.8 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $59.3 million, with a median of $62.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 47.05% in 2022, then rose 1.75% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $45.5 million in 2021, then surged by 35.0% to $61.4 million in 2022, then increased by 2.05% to $62.6 million in 2023, then increased by 3.03% to $64.5 million in 2024, then rose by 3.21% to $66.6 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Shares Outstanding (Weighted Average) are $66.6 million (Q4 2025), $66.5 million (Q3 2025), and $66.3 million (Q2 2025).